Iovance Biotherapeutics, Inc.
- IOVA
- NASDAQ
- Biotechnology
- Cancer Immunotherapy
- TIL Cell Therapy
$14.21
Today +4.33%Quote Oct 19, 2026, 08:00 PM UTC
+38.63%over the last month
Max drawdown −12.8%From 1-month high −4.1%3 months +159.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
975
Market value
$6.44B
Quote Oct 19
Floor
$13.99
1.6% below price
Resistance
$14.45
1.7% above price
Price vs analyst targets
21 analysts
Lowest target
$5.00Highest target
$20.00
$5.00Highest target
$20.00
- Price $14.21
- Average target $13.44
- Analysts' target range
Analysts' average target sits about 5% lower. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about IOVAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free